glp-1 drug market competition 2025 Agonists Exclusive Research Report GLP-1 Agonists Weight Loss Drugs
Description
Prior analyses have either used models that exclude the results of cardiovascular outcomes trials (with any reductions in cardiovascular and kidney outcomes being extrapolated only from changes in HbA 1c [13]), considered only specific high-risk populations [45, 46], or modelled the populations used in cardiovascular outcomes trials, which represent only 2060% of all people with type 2 diabetes [14]
Don't wait to address your health concerns
L., Bremser S., Alber J., Giavalisco P., et al
Ongoing research into nutritional and exercise interventions, as well as novel pharmacological agents such as myostatin/activin pathway inhibitors (243) or agents targeting the apelin pathway (244) holds promise for preserving lean mass and improving overall health in patients undergoing treatment with GLP-1 and dual GIP/GLP-1 receptor agonists
The challenge is to support innovation while maintaining clinical standards and patient protection
iScience 26 , 106848 (2023)
